Medico Remedies Ltd (MEDICO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 1002925, "name": "Medico Remedies", "stock_name": "Medico Remedies", "full_name": "Medico Remedies Ltd", "name_url": "stocks-analysis/medico-remedies", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "37.85", "chg": -1.23, "chgp": "-3.15%", "dir": -1, "prev_price": "39.08", "mcapval": "321.00 Cr", "mcap": "Micro Cap", "scripcode": 540937, "symbol": "MEDICO", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "India SENSEX", "isin": "INE630Y01024", "curr_date": "Apr 09", "curr_time": "", "bse_nse_vol": "1.61 lacs", "exc_status": "Active", "traded_date": "Apr 09, 2026", "traded_date_str": "2026 04 09", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/medico-remedies-1002925-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Medico Remedies Gains 13.27%: Key Valuation and Rating Shifts Shape the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/medico-remedies-gains-1327-key-valuation-and-rating-shifts-shape-the-week-3931881", "imagepath": "", "date": "2026-04-04 13:02:39", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>30 Mar:</strong> Stock hits 52-week low at Rs.31 amid market downturn</p>\n <p><strong>30 Mar:</strong> MarketsMOJO upgrades rating to Hold citing improved valuation</p>\n <p><strong>30 Mar:</strong> Valuation metrics shift to attractive, signalling price appeal</p>\n <p><strong>2 Apr:</strong> Downgrade to Sell issued despite recent profit growth</p>\n <p><strong>2 Apr:</strong> Week closes at Rs.37.81, up 13.27% vs Sensex down 0.29%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.3..." }, { "title": "Medico Remedies Downgraded to Sell Amid Mixed Financials and Valuation Shift", "link": "https://www.marketsmojo.com/news/stock-recommendation/medico-remedies-downgraded-to-sell-amid-mixed-financials-and-valuation-shift-3929697", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/MedicoRemediesL_mojoScore_3929697.png", "date": "2026-04-02 08:32:29", "description": "Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell despite an upgrade in its valuation grade from fair to attractive. This shift, effective from 1 April 2026, reflects a complex interplay of factors including valuation metrics, financial trends, quality assessments, and technical indicators, which together paint a nuanced picture for investors." }, { "title": "Five Consecutive Losses Push Medico Remedies Ltd to a New 52-Week Low", "link": "https://www.marketsmojo.com/news/stocks-in-action/medico-remedies-ltd-falls-to-52-week-low-of-rs31-amid-market-downturn-3925341", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/MedicoRemediesL_priceRelatedfactors_3925341.png", "date": "2026-03-30 14:30:34", "description": "For the fifth consecutive session, Medico Remedies Ltd has closed lower, culminating in a fresh 52-week low of Rs 31 on 30 Mar 2026. This decline comes amid a broader market downturn, but the stock's underperformance is notably sharper than its sector peers." }, { "title": "Medico Remedies Ltd Upgraded to Hold as Valuation and Financials Improve", "link": "https://www.marketsmojo.com/news/stock-recommendation/medico-remedies-ltd-upgraded-to-hold-as-valuation-and-financials-improve-3923541", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/MedicoRemediesL_mojoScore_3923541.png", "date": "2026-03-30 08:11:01", "description": "Medico Remedies Ltd has seen its investment rating upgraded from Sell to Hold as of 27 March 2026, reflecting a marked improvement in valuation metrics and financial performance despite recent share price weakness. The pharmaceutical company’s enhanced score is driven primarily by a shift to an attractive valuation grade, supported by robust return on capital employed (ROCE), steady financial trends, and a cautiously optimistic technical outlook." }, { "title": "Medico Remedies Ltd Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/medico-remedies-ltd-valuation-shifts-signal-renewed-price-attractiveness-3923375", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/MedicoRemediesL_valuationdot_3923375.png", "date": "2026-03-30 08:01:50", "description": "Medico Remedies Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, reflecting a more compelling price proposition for investors. Despite recent share price declines, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now suggest improved relative value compared to historical levels and peer benchmarks within the Pharmaceuticals & Biotechnology sector." }, { "title": "Medico Remedies Ltd Falls to 52-Week Low of Rs 33.78 as Sell-Off Deepens", "link": "https://www.marketsmojo.com/news/stocks-in-action/medico-remedies-ltd-falls-to-52-week-low-amid-continued-market-pressure-3919997", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/MedicoRemediesL_priceRelatedfactors_3919997.png", "date": "2026-03-27 14:46:03", "description": "A sharp decline in Medico Remedies Ltd has pushed the stock to a fresh 52-week low of Rs 33.78 on 27 Mar 2026, marking a significant 6.22% intraday drop amid broader market weakness. This latest fall extends the stock’s losing streak to two consecutive sessions, reflecting persistent selling pressure despite the company’s recent positive financial results." }, { "title": "Medico Remedies Ltd Falls to 52-Week Low of Rs 34 as Sell-Off Deepens", "link": "https://www.marketsmojo.com/news/stocks-in-action/medico-remedies-ltd-falls-to-52-week-low-of-rs34-amid-sector-and-market-downturn-3908360", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/MedicoRemediesL_priceRelatedfactors_3908360.png", "date": "2026-03-23 15:54:21", "description": "A sharp decline of 10.69% today dragged Medico Remedies Ltd to a fresh 52-week low of Rs 34, extending a downward trajectory that has seen the stock underperform the broader market significantly over the past year." }, { "title": "Medico Remedies Falls 3.91%: Death Cross and Downgrade Signal Bearish Momentum", "link": "https://www.marketsmojo.com/news/stocks-in-action/medico-remedies-falls-391-death-cross-and-downgrade-signal-bearish-momentum-3905180", "imagepath": "", "date": "2026-03-21 13:02:24", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>16 Mar:</strong> Stock opens at Rs.39.18, down 1.11% amid Sensex gains</p>\n <p><strong>18 Mar:</strong> Death Cross formation signals potential bearish trend</p>\n <p><strong>19 Mar:</strong> Downgrade to 'Sell' rating amid technical weakness</p>\n <p><strong>20 Mar:</strong> Slight recovery to Rs.38.07, but weekly loss persists</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.39.62</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">R..." }, { "title": "Medico Remedies Downgraded to Sell Amid Technical Weakness and Prolonged Underperformance", "link": "https://www.marketsmojo.com/news/stock-recommendation/medico-remedies-downgraded-to-sell-amid-technical-weakness-and-prolonged-underperformance-3899851", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/MedicoRemediesL_mojoScore_3899851.png", "date": "2026-03-19 08:15:07", "description": "Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 18 March 2026. This shift reflects a deterioration in technical indicators alongside persistent underperformance against benchmarks, despite solid financial fundamentals. The downgrade is driven primarily by a bearish technical outlook, valuation concerns, and a disappointing trend in stock returns over recent years." } ], "total": 179, "sid": "1002925", "stock_news_url": "https://www.marketsmojo.com/news/medico-remedies-1002925" }, "announcements": [ { "caption": "Clarification With Regards To Additional Details Sought In Respect Of Outcome Of Board Meeting Held On 18Th February 2026 Submitted To Exchange On 18Th February 2026", "datetime": "24-Feb-2026", "details": "Please find enclosed", "source": "BSE" }, { "caption": "Intimation Of Action Taken Or Order Passed By Regulatory Statutory Enforcement Authority Or Judicial Body Under Regulation 30 (Read With Part B Of Schedule III) (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)", "datetime": "24-Feb-2026", "details": "Please find enclosed", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Change in Management", "datetime": "18-Feb-2026", "details": "Please find enclosed", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Medico Remedies Ltd has announced <strong>2:10</strong> stock split, ex-date: 16 Mar 23", "dt": "2023-03-16", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "", "data": [ { "txt": "Medico Remedies Ltd has announced <strong>3:1</strong> bonus issue, ex-date: 16 Nov 21", "dt": "2021-11-16", "middle_text": "Bonus Alert" } ] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

30 Mar: Stock hits 52-week low at Rs.31 amid market downturn

30 Mar: MarketsMOJO upgrades rating to Hold citing improved valuation

30 Mar: Valuation metrics shift to attractive, signalling price appeal

2 Apr: Downgrade to Sell issued despite recent profit growth

2 Apr: Week closes at Rs.37.81, up 13.27% vs Sensex down 0.29%

Week Open

Rs.3...

Read full news article

Medico Remedies Downgraded to Sell Amid Mixed Financials and Valuation Shift

2026-04-02 08:32:29

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell despite an upgrade in its valuation grade from fair to attractive. This shift, effective from 1 April 2026, reflects a complex interplay of factors including valuation metrics, financial trends, quality assessments, and technical indicators, which together paint a nuanced picture for investors.

Read full news article

Five Consecutive Losses Push Medico Remedies Ltd to a New 52-Week Low

2026-03-30 14:30:34

For the fifth consecutive session, Medico Remedies Ltd has closed lower, culminating in a fresh 52-week low of Rs 31 on 30 Mar 2026. This decline comes amid a broader market downturn, but the stock's underperformance is notably sharper than its sector peers.

Read full news article

Medico Remedies Ltd Upgraded to Hold as Valuation and Financials Improve

2026-03-30 08:11:01

Medico Remedies Ltd has seen its investment rating upgraded from Sell to Hold as of 27 March 2026, reflecting a marked improvement in valuation metrics and financial performance despite recent share price weakness. The pharmaceutical company’s enhanced score is driven primarily by a shift to an attractive valuation grade, supported by robust return on capital employed (ROCE), steady financial trends, and a cautiously optimistic technical outlook.

Read full news article

Medico Remedies Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-03-30 08:01:50

Medico Remedies Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, reflecting a more compelling price proposition for investors. Despite recent share price declines, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now suggest improved relative value compared to historical levels and peer benchmarks within the Pharmaceuticals & Biotechnology sector.

Read full news article

Medico Remedies Ltd Falls to 52-Week Low of Rs 33.78 as Sell-Off Deepens

2026-03-27 14:46:03

A sharp decline in Medico Remedies Ltd has pushed the stock to a fresh 52-week low of Rs 33.78 on 27 Mar 2026, marking a significant 6.22% intraday drop amid broader market weakness. This latest fall extends the stock’s losing streak to two consecutive sessions, reflecting persistent selling pressure despite the company’s recent positive financial results.

Read full news article

Medico Remedies Ltd Falls to 52-Week Low of Rs 34 as Sell-Off Deepens

2026-03-23 15:54:21

A sharp decline of 10.69% today dragged Medico Remedies Ltd to a fresh 52-week low of Rs 34, extending a downward trajectory that has seen the stock underperform the broader market significantly over the past year.

Read full news article

Medico Remedies Falls 3.91%: Death Cross and Downgrade Signal Bearish Momentum

2026-03-21 13:02:24

Key Events This Week

16 Mar: Stock opens at Rs.39.18, down 1.11% amid Sensex gains

18 Mar: Death Cross formation signals potential bearish trend

19 Mar: Downgrade to 'Sell' rating amid technical weakness

20 Mar: Slight recovery to Rs.38.07, but weekly loss persists

Read full news article

Medico Remedies Downgraded to Sell Amid Technical Weakness and Prolonged Underperformance

2026-03-19 08:15:07

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 18 March 2026. This shift reflects a deterioration in technical indicators alongside persistent underperformance against benchmarks, despite solid financial fundamentals. The downgrade is driven primarily by a bearish technical outlook, valuation concerns, and a disappointing trend in stock returns over recent years.

Read full news article

View All News